Pfizer reached a last-minute deal with the Trump administration in late September to lower drug prices and avoid sweeping pharmaceutical tariffs. Negotiations accelerated in the days before a White House deadline, with CEO Albert Bourla and Health Secretary Robert F. Kennedy Jr. finalizing the agreement hours before the announcement. For Trump, the deal was a political win that showcased progress on drug costs; for Pfizer, it was a way to neutralize tariff threats with minimal impact on its bottom line, the Wall Street Journal reported.

What Pfizer agreed to

Under the agreement, Pfizer will extend “most-favoured-nation” pricing to Medicaid, ensuring the US government pays no more than wealthy countries for its medicines. The company also pledged to launch new drugs at parity with interna

See Full Page